Cargando…

Human cancer evolution in the context of a human immune system in mice

Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammelgaard, Odd L., Terp, Mikkel G., Preiss, Birgitte, Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165999/
https://www.ncbi.nlm.nih.gov/pubmed/30120895
http://dx.doi.org/10.1002/1878-0261.12374
_version_ 1783359953262608384
author Gammelgaard, Odd L.
Terp, Mikkel G.
Preiss, Birgitte
Ditzel, Henrik J.
author_facet Gammelgaard, Odd L.
Terp, Mikkel G.
Preiss, Birgitte
Ditzel, Henrik J.
author_sort Gammelgaard, Odd L.
collection PubMed
description Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in humanized immune system (HIS) mice created by transfer of CD34+ human hematopoietic stem cells. All tested transplanted cancer cell lines developed primary tumors that progressed nearly synchronously. Spontaneous lung and liver metastases developed from both orthotopic and ectopic transplanted cancer cells, and the ability to spread inversely correlated with the extent of CD8+ infiltration in the primary tumor. Further analysis revealed that interactions between the cancer model and the tumor‐infiltrating lymphocytes created tumor microenvironments (TMEs) resembling clinical cancers. Some models were largely immune cell‐excluding, while others appeared to develop adaptive resistance to immune‐mediated destruction by increased expression of programmed death ligand 1 (PDL1) and recruitment of human regulatory T cells. Our data suggest that HIS mice may provide a promising in vivo tumor model for evaluating immune modulatory anticancer therapies. Moreover, our study identified different tumor models resembling specific types of human TMEs, rendering each beneficial for addressing disease‐specific issues.
format Online
Article
Text
id pubmed-6165999
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61659992018-10-04 Human cancer evolution in the context of a human immune system in mice Gammelgaard, Odd L. Terp, Mikkel G. Preiss, Birgitte Ditzel, Henrik J. Mol Oncol Research Articles Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in humanized immune system (HIS) mice created by transfer of CD34+ human hematopoietic stem cells. All tested transplanted cancer cell lines developed primary tumors that progressed nearly synchronously. Spontaneous lung and liver metastases developed from both orthotopic and ectopic transplanted cancer cells, and the ability to spread inversely correlated with the extent of CD8+ infiltration in the primary tumor. Further analysis revealed that interactions between the cancer model and the tumor‐infiltrating lymphocytes created tumor microenvironments (TMEs) resembling clinical cancers. Some models were largely immune cell‐excluding, while others appeared to develop adaptive resistance to immune‐mediated destruction by increased expression of programmed death ligand 1 (PDL1) and recruitment of human regulatory T cells. Our data suggest that HIS mice may provide a promising in vivo tumor model for evaluating immune modulatory anticancer therapies. Moreover, our study identified different tumor models resembling specific types of human TMEs, rendering each beneficial for addressing disease‐specific issues. John Wiley and Sons Inc. 2018-09-03 2018-10 /pmc/articles/PMC6165999/ /pubmed/30120895 http://dx.doi.org/10.1002/1878-0261.12374 Text en © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Gammelgaard, Odd L.
Terp, Mikkel G.
Preiss, Birgitte
Ditzel, Henrik J.
Human cancer evolution in the context of a human immune system in mice
title Human cancer evolution in the context of a human immune system in mice
title_full Human cancer evolution in the context of a human immune system in mice
title_fullStr Human cancer evolution in the context of a human immune system in mice
title_full_unstemmed Human cancer evolution in the context of a human immune system in mice
title_short Human cancer evolution in the context of a human immune system in mice
title_sort human cancer evolution in the context of a human immune system in mice
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165999/
https://www.ncbi.nlm.nih.gov/pubmed/30120895
http://dx.doi.org/10.1002/1878-0261.12374
work_keys_str_mv AT gammelgaardoddl humancancerevolutioninthecontextofahumanimmunesysteminmice
AT terpmikkelg humancancerevolutioninthecontextofahumanimmunesysteminmice
AT preissbirgitte humancancerevolutioninthecontextofahumanimmunesysteminmice
AT ditzelhenrikj humancancerevolutioninthecontextofahumanimmunesysteminmice